Scientists probe immune system secrets behind vaccines that protect for decades

NCT ID NCT05801978

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 17, 2026 · Last updated Jul 17, 2026

Summary

This study compares two vaccines with very different track records: the yellow fever vaccine, which protects for decades after a single shot, and the seasonal flu vaccine, whose protection fades quickly. Healthy adults aged 18–50 receive either the yellow fever or flu vaccine, and researchers collect blood samples over time to analyze immune responses. The goal is to identify biological signals that predict long-lasting immunity, which could guide the development of more durable vaccines in the future.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Live attenuated yellow fever vaccine (YF-17D) or quadrivalent seasonal influenza vaccine
What this could lead to
If successful, this research could reveal biological markers that predict long-lasting vaccine protection, helping design better vaccines in the future.
What could go wrong
This is an observational comparison, not a test of new treatments. The findings may not translate into practical improvements for vaccine development.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 66 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2023

Expected to finish

Sep 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 50 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Able to understand and give informed consent. * Age 18-50 years. * Participants agree not to take any live vaccines 30 days before or after (14 days for inactivated) vaccination. * Women of child bearing potential must agree to use effective birth control for the first 3 months of the study. A negative urine pregnancy test must be documented prior to vaccination and prior to tissue sampling procedures. Exclusion Criteria: * History of allergy or serious adverse reaction, including Guillain-Barré syndrome, to a vaccine or vaccine products. * History of a medical condition resulting in impaired immunity (such as HIV infection, cancer, particularly leukemia, lymphoma, use of immunosuppressive or antineoplastic drugs or X-ray treatment). Persons with previous skin cancers or cured non-lymphatic tumors are not excluded from the study. * History of Hepatitis B or Hepatitis C infection. * Chronic clinically significant medical problems that could affect the immune response, require medication that would affect the immune response, or have signs or symptoms that could be confused with reactions to vaccination, including (but not limited to): 1. Insulin dependent diabetes 2. Severe heart disease (including arrhythmias) 3. Severe lung disease 4. Severe liver disease 5. Severe kidney disease 6. Grade 4 hypertension (\*Grade 4 hypertension per CTCAE criteria is defined as life-threatening consequences (e.g., malignant hypertension, transient or permanent neurologic deficit)) * Thymus gland problems (such as myasthenia gravis, DiGeorge syndrome, thymoma) or removal of thymus gland or history of uncontrolled autoimmune disorder. * Pregnancy or breast feeding, or plans to become pregnant in the first 3 months of study participation. * Receipt of blood products or immune globulin product within the prior 3 months. * Active duty military. * History of excessive alcohol consumption, drug use, psychiatric conditions, social conditions or occupational conditions that in the opinion of the investigator would preclude compliance with the trial. Additional Exclusion Criteria for YF-17D Arm * History of previous yellow fever, West Nile, Dengue, St. Louis encephalitis, or Japanese encephalitis vaccination or infection. * Previous residence in a country where there is a risk of yellow fever virus (YFV) transmission * History of allergy to eggs, chicken, or gelatin. Additional Exclusion Criteria for QIV Arm * History of influenza infection within the same influenza season.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Vaccine response are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Emory University Hospital

    RECRUITING

    Atlanta, Georgia, 30322, United States

  • Emory Winship Cancer Institute

    RECRUITING

    Atlanta, Georgia, 30322, United States

  • The Hope Clinic of Emory University

    RECRUITING

    Decatur, Georgia, 30030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.